Literature DB >> 22696597

NDRG2 correlated with favorable recurrence-free survival inhibits metastasis of mouse breast cancer cells via attenuation of active TGF-β production.

Sang-seok Oh1, Donghyeok Kim, Dong-Hee Kim, Hong Hee Chang, Kyung-Cheol Sohn, Kyo Hyun Kim, Sung Hoo Jung, Byoung Kil Lee, Joo Heon Kim, Kwang Dong Kim.   

Abstract

N-myc downstream-regulated gene 2 (NDRG2) has been studied for its inhibitory effects against growth and metastasis of many tumor cell types. In this study, we showed NDRG2 expression was correlated with favorable recurrence-free survival of patients with breast cancer and inhibited metastasis of breast cancer cells (4T1). NDRG2 expression was examined in 189 breast carcinoma tissues and paired normal breast tissues using immunohistochemistry. Histological and clinicopathological data were correlated using Pearson's chi-square test of independence. NDRG2 expression in human breast cancer tissues was inversely associated with lymph node metastasis and pTNM stage. Furthermore, patients with breast cancer with a high level of NDRG2 expression showed favorable recurrence-free survival (P = 0.038). To study the effect of NDRG2 on metastasis in vivo, we established an NDRG2-overexpressing mouse breast cancer cell line (4T1-NDRG2) and measured the metastasis and survival of 4T1-NDRG2 tumor-bearing mice. To test whether transforming growth factor β (TGF-β)- mediated metastasis of 4T1 was inhibited by NDRG2 expression, TGF-Smad-binding element (SBE)-luciferase activity and/or measurement of active TGF-β were performed in cell or tumor tissue level. 4T1-NDRG2 cells grew gradually and showed less metastatic activity in vivo and low invasiveness in vitro. 4T1-NDRG2 cells showed lower SBE-luciferase activity and lower level of active autocrine TGF-β than 4T1-Mock did. Correctly, our data show that NDRG2 significantly suppress tumor metastasis by attenuating active autocrine TGF-β production, and the attenuation might be typically associated with the favorable recurrence-free survival of patients clinically.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22696597     DOI: 10.1093/carcin/bgs211

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  14 in total

1.  N-myc downstream-regulated gene 2 expression is associated with glucose transport and correlated with prognosis in breast carcinoma.

Authors:  Ji Ma; Wenchao Liu; Hang Guo; Shaoqing Li; Wei Cao; Xilin Du; Shixiong Lei; Wugang Hou; Lize Xiong; Libo Yao; Nanlin Li; Yan Li
Journal:  Breast Cancer Res       Date:  2014-03-18       Impact factor: 6.466

2.  The iron chelator Dp44mT inhibits hepatocellular carcinoma metastasis via N-Myc downstream-regulated gene 2 (NDRG2)/gp130/STAT3 pathway.

Authors:  Jiabei Wang; Dalong Yin; Changming Xie; Tongsen Zheng; Yingjian Liang; Xuehui Hong; Zhaoyang Lu; Xuan Song; Ruipeng Song; Haiyan Yang; Boshi Sun; Nishant Bhatta; Xianzhi Meng; Shangha Pan; Hongchi Jiang; Lianxin Liu
Journal:  Oncotarget       Date:  2014-09-30

3.  NDRG2 overexpression enhances glucose deprivation-mediated apoptosis in breast cancer cells via inhibition of the LKB1-AMPK pathway.

Authors:  Hak-Su Kim; Myung-Jin Kim; Jihyun Lim; Young Yang; Myeong-Sok Lee; Jong-Seok Lim
Journal:  Genes Cancer       Date:  2014-05

4.  NDRG2 controls COX-2/PGE₂-mediated breast cancer cell migration and invasion.

Authors:  Myung-Jin Kim; Hak-Su Kim; Soo-Hwan Lee; Young Yang; Myeong-Sok Lee; Jong-Seok Lim
Journal:  Mol Cells       Date:  2014-09-26       Impact factor: 5.034

5.  Abundant NDRG2 Expression Is Associated with Aggressiveness and Unfavorable Patients' Outcome in Basal-Like Breast Cancer.

Authors:  Vera Kloten; Martin Schlensog; Julian Eschenbruch; Janina Gasthaus; Janina Tiedemann; Jolein Mijnes; Timon Heide; Till Braunschweig; Ruth Knüchel; Edgar Dahl
Journal:  PLoS One       Date:  2016-07-11       Impact factor: 3.240

6.  NDRG2 Expression Decreases Tumor-Induced Osteoclast Differentiation by Down-regulating ICAM1 in Breast Cancer Cells.

Authors:  Bomi Kim; Sorim Nam; Ji Hyun Lim; Jong-Seok Lim
Journal:  Biomol Ther (Seoul)       Date:  2016-01-01       Impact factor: 4.634

7.  NDRG2 Sensitizes Myeloid Leukemia to Arsenic Trioxide via GSK3β-NDRG2-PP2A Complex Formation.

Authors:  Soojong Park; Hyun-Tak Han; Sang-Seok Oh; Dong Hyeok Kim; Jin-Woo Jeong; Ki Won Lee; Minju Kim; Jong Seok Lim; Yong Yeon Cho; Cheol Hwangbo; Jiyun Yoo; Kwang Dong Kim
Journal:  Cells       Date:  2019-05-22       Impact factor: 6.600

8.  Clinical Potentials of miR-576-3p, miR-613, NDRG2 and YKL40 in Colorectal Cancer Patients.

Authors:  Manal Nasreddin Eldaly; Fateheya Mohamed Metwally; Wafaa Ghoneim Shousha; Abeer Salah El-Saiid; Shimaa Shawki Ramadan
Journal:  Asian Pac J Cancer Prev       Date:  2020-06-01

9.  Tumor suppressor NDRG2 tips the balance of oncogenic TGF-β via EMT inhibition in colorectal cancer.

Authors:  L Shen; X Qu; Y Ma; J Zheng; D Chu; B Liu; X Li; M Wang; C Xu; N Liu; L Yao; J Zhang
Journal:  Oncogenesis       Date:  2014-02-03       Impact factor: 7.485

10.  NDRG2 contributes to cisplatin sensitivity through modulation of BAK-to-Mcl-1 ratio.

Authors:  Soojong Park; Sang-Seok Oh; Ki Won Lee; Yeon-Kyeong Lee; Nae Yu Kim; Joo Heon Kim; Jiyun Yoo; Kwang Dong Kim
Journal:  Cell Death Dis       Date:  2018-01-18       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.